Sangamo Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SGMO Nasdaq 2830 www.sangamo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Jun 24th, 2025 6:05 am
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - May 13th, 2025 11:01 am
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - May 12th, 2025 4:26 pm
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - May 12th, 2025 4:23 pm
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2025 3:55 pm
Sangamo: Q1 Earnings Snapshot - May 12th, 2025 2:53 pm
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - May 12th, 2025 2:00 pm
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - May 6th, 2025 2:35 pm
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - May 6th, 2025 6:30 am
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - May 1st, 2025 8:01 am
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Apr 28th, 2025 2:31 pm
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Apr 3rd, 2025 2:01 pm
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Mar 18th, 2025 1:01 am
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Mar 17th, 2025 3:10 pm
Sangamo: Q4 Earnings Snapshot - Mar 17th, 2025 2:20 pm
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Mar 17th, 2025 2:01 pm
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Mar 6th, 2025 3:58 pm
Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89% - Feb 28th, 2025 5:38 am
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - Feb 6th, 2025 6:05 am
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - Jan 7th, 2025 9:32 am